European Union

Alteia signs €15 million financing agreement with EIB to accelerate its development in the deep tech field of artificial intelligence applied to visual data

Thursday, December 2, 2021 - 12:28am

The European Investment Bank (EIB) and Toulouse-based startup Alteia, which specializes in the development of artificial intelligence software, have announced the signature of a 15 million financing agreement.

Key Points: 
  • The European Investment Bank (EIB) and Toulouse-based startup Alteia, which specializes in the development of artificial intelligence software, have announced the signature of a 15 million financing agreement.
  • It is part of the EIB's strategy to strengthen innovation in the deep tech sector and the European Union's competitiveness in the strategic field of industrial artificial intelligence and data processing.
  • The operation aims to enable Alteia to continue its development of technologies in the field of artificial intelligence applied to visual data and support the growth and visibility of its enterprise platform.
  • Alteia is the visual intelligence platform for enterprises, which are provided with access to tools and services to develop artificial intelligence applications in a much more efficient and cost-effective manner than alternative approaches.

Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit

Wednesday, December 1, 2021 - 9:07pm

Investors will have the opportunity to schedule one-on-one meetings with the presenting companies management teams to discuss development and commercial plans in further detail.

Key Points: 
  • Investors will have the opportunity to schedule one-on-one meetings with the presenting companies management teams to discuss development and commercial plans in further detail.
  • Gain Therapeutics is a Member of the AAIH and Gains Chief Scientific Officer, Xavier Barril, Ph.D., is a member of AAIHs Technology & Standards Development Committee.
  • Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx target identification platform.
  • In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

Wednesday, December 1, 2021 - 10:01pm

We are pleased to see the publication of these highly positive interim Phase 3 results in a leading peer-reviewed scientific publication like NEJM Evidence, said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio.

Key Points: 
  • We are pleased to see the publication of these highly positive interim Phase 3 results in a leading peer-reviewed scientific publication like NEJM Evidence, said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.
  • These results are consistent with the results observed in healthy younger subjects treated with ticagrelor in the previously published Phase 1 trial.
  • PhaseBio initiated REVERSE-IT, a pivotal Phase 3 clinical trial of bentracimab, in March 2020 to support a potential Biologics License Application for bentracimab in both major bleeding and urgent surgery indications.

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

Wednesday, December 1, 2021 - 9:05pm

"We believe orphan-drug designation underscores the recognition of INBRX-109 as a promising therapeutic for patientswith metastatic or unresectable chondrosarcoma, a patient community currently with no other viable options," said Inhibrx Chief Executive Officer Mark Lappe.

Key Points: 
  • "We believe orphan-drug designation underscores the recognition of INBRX-109 as a promising therapeutic for patientswith metastatic or unresectable chondrosarcoma, a patient community currently with no other viable options," said Inhibrx Chief Executive Officer Mark Lappe.
  • Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the European Union.
  • In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
  • In June 2021, Inhibrx initiated a randomized, blinded, placebo-controlled, potential registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma.

Global Kitchen Furniture Market Outlook to 2024 - Company Profiles for 40 Main Manufacturers - ResearchAndMarkets.com

Wednesday, December 1, 2021 - 6:14pm

The report identifies the opportunities that arise in the global kitchen furniture market and it is a helpful tool for companies exporting kitchen furniture as it contains a rich collection of key country data, allowing comparisons among different areas.

Key Points: 
  • The report identifies the opportunities that arise in the global kitchen furniture market and it is a helpful tool for companies exporting kitchen furniture as it contains a rich collection of key country data, allowing comparisons among different areas.
  • Production and consumption of kitchen furniture are given at world level and by country, both in value and units.
  • International trade statistics of kitchen furniture by country of origin/destination are included, as well as trade balance data covering the years 2015-2020.
  • Kitchen furniture consumption by geographical region, 2019, 2020 and preliminary 2021
    World market of kitchen furniture production and consumption: focus on 60 countries.

Halfords Group PLC: Retail Offer by PrimaryBid

Wednesday, December 1, 2021 - 5:09pm

The distribution of this announcement and the offering, placing and/or issue of the Retail Offer Shares in certain jurisdictions may be restricted by law.

Key Points: 
  • The distribution of this announcement and the offering, placing and/or issue of the Retail Offer Shares in certain jurisdictions may be restricted by law.
  • No action has been taken by the Company, PrimaryBid or any of their respective affiliates, or any person acting on any of their behalves, that would permit an offer of the Retail Offer Shares or possession or distribution of this announcement or any other offering or publicity material relating to such Retail Offer Shares in any jurisdiction where action for that purpose is required.
  • No public offering of the Retail Offer Shares, the Placing Shares or any other securities is being made in the United States.
  • The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

DGAP-News: Change in Newron Board of Directors

Wednesday, December 1, 2021 - 5:09pm

Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Directors of his intention to step down as a Non-Executive member of the Board of Directors, effective December 31, 2021.

Key Points: 
  • Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Directors of his intention to step down as a Non-Executive member of the Board of Directors, effective December 31, 2021.
  • Ulrich Kstlin, Chairman of Newron, commented: "The Board of Directors and I would like to thank Bob for his dedication and commitment to Newron since he joined the Board in 2013.
  • At this time, Newron does not anticipate making any Non-Executive Director appointments.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

American Express Company Announces Expiration and Final Results of the Exchange Offer and Consent Solicitation for Certain American Express Credit Corporation Notes

Wednesday, December 1, 2021 - 5:00pm

King & Co., Inc. was the exchange agent and information agent in connection with the Exchange Offer and Consent Solicitation and can be contacted at (866) 356-7814 (U.S. toll-free) or (212) 269-5550 (banks and brokers).

Key Points: 
  • King & Co., Inc. was the exchange agent and information agent in connection with the Exchange Offer and Consent Solicitation and can be contacted at (866) 356-7814 (U.S. toll-free) or (212) 269-5550 (banks and brokers).
  • American Express will also agree to use reasonable best efforts to file a shelf registration statement to cover resales of the AXP Notes under certain circumstances.
  • No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
  • American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success.

Sun Genomics Expands Into Europe via Partnership with The Swiss Integrative Center for Human Health

Wednesday, December 1, 2021 - 3:00pm

Since its founding in 2016, Sun Genomics has serviced tens of thousands of customers across the U.S. with its Flor precision gut health offering.

Key Points: 
  • Since its founding in 2016, Sun Genomics has serviced tens of thousands of customers across the U.S. with its Flor precision gut health offering.
  • Given its significant growth in 2021, following a successful Series A fundraise, Sun Genomics is expanding its footprint internationally.
  • Sun Genomics has seen tremendous interest from international customers and strategic partners as people begin to focus more on their gut health, said Sunny Jain, CEO and Founder of Sun Genomics.
  • As we began to explore international locations, the connection to The Swiss Integrative Center for Human Health became instrumental in our decision to expand.

DGAP-News: SynBiotic SE: Most important cannabis merger in Europe

Wednesday, December 1, 2021 - 2:25pm

It is the most significant merger in the European cannabis sector.

Key Points: 
  • It is the most significant merger in the European cannabis sector.
  • With Daniel Kruse's four companies, Hanf Farm GmbH, Hempro International GmbH, Hemp Factory GmbH and MH medical hemp GmbH, SynBiotic SE's portfolio is being enriched by important infrastructures and profitable brands.
  • Lars Mller, CEO of SynBiotic SE: "The cooperation with Daniel Kruse is a genuine accolade in the cannabis sector.
  • SynBiotic SE will benefit massively from what amounts to over half a century of combined know-how gathered by industry pioneers Daniel Kruse and Rafael Dulon.